Showing 1131-1140 of 1779 results for "".
- FDA Approves StrataGraft for the Treatment of Adults with Thermal Burnshttps://practicaldermatology.com/news/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns/2460839/The U.S. Food and Drug Administration approved StrataGraft for the treatment of adult deep partial thickness burns. "Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient ret
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.
- Indoor Tanning Linked to Anxiety, Depressionhttps://practicaldermatology.com/news/indoor-tanning-linked-to-anxiety-depression/2460808/Indoor tanning early in life is associated with risk of anxiety and depression later in life, according to new research in the Journal of the American Academy of Dermatology. Excluding women wi
- Minimizing Risks of Cosmetic Procedures in Patients with Darker Skin Typeshttps://practicaldermatology.com/news/minimizing-risks-of-cosmetic-procedures-in-patients-with-darker-skin-types/2460784/With cosmetic procedures in high demand during the pandemic, Cedars-Sinai dermatologist Jasmine Obioha, MD, has seen an unfortunate side effect: botched treatments for patients of color. When performed improperly, procedures such as chemical peels and laser hair removal can inflame and
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- Study Documents Arm, Skin Rashes After COVID-19 Vaccinationshttps://practicaldermatology.com/news/study-documents-covid-vaccine-arm-skin-rashes-after-covid-19-vaccinations/2460737/As COVID-19 vaccination ramps up globally, new research in the Journal of the American Academy of Dermatology demonstrates the wide variety of skin rashes, including full-body rashes, observed after COVID
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in a
- Differin Celebrates Retinoid Awareness Week with Educational Initiativeshttps://practicaldermatology.com/news/differin-celebrates-retinoid-awareness-week-with-educational-initiatives/2460710/Following the FDA approval of Differin Gel to be sold over the-counter in 2016, Galderma embarked on a journey to educate consumers about retinoids like adapalene. In 2017, Differin launched its first ever Retinoid Education Week to continue to drive awareness. Now in its fourth year, D